Repair Bio targets free cholesterol in liver
Cardiovascular disease is the leading cause of death worldwide. Most treatments slow its progression. Repair Biotechnologies is trying to reverse it by targeting excess cholesterol directly inside liver cells.
The company’s lead drug candidate is called REP-0004. It focuses on the liver, where an accumulation of free cholesterol inside cells causes damage. This is a different mechanism from most existing cholesterol-lowering drugs, which primarily reduce LDL cholesterol in the bloodstream.
The reasoning is that free cholesterol inside liver cells contributes to systemic inflammation and atherosclerosis (the build-up of plaques in blood vessels). By reducing that cholesterol at the cellular level, the company aims to intervene earlier in the disease process. The researchers at Repair Bio have received orphan drug designation from the FDA, which accelerates clinical development.
Clinical trials planned for 2027
The company is targeting the start of human clinical trials in the first half of 2027. Toxicity studies and additional preclinical data need to be completed before that point.
The approach fits a broader trend in the longevity field: instead of managing symptoms, remove causes. Other companies are pursuing similar strategies, such as removing oxidised cholesterol from foam cells (macrophages filled with lipid waste) inside blood vessel walls.
What sets this approach apart
The focus on the liver rather than the blood vessels is notable. The liver is the central regulator of cholesterol metabolism. An intervention there may have broader effects than treating plaques locally in vessels.
Whether REP-0004 is effective and safe in humans is for the clinical phase to determine. The mechanism is biologically well-supported, and the orphan drug status gives the company additional resources to prove it.
Want to research this yourself?
Search for terms like: liver cholesterol heart disease